| 產品名稱 | L-alpha-2A L-cells |
|---|---|
| 商品貨號 | B220594 |
| Organism | Mus musculus, mouse |
| Product Format | frozen |
| Morphology | fibroblast |
| Culture Properties | adherent, single cells and loosely attached clusters |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Age | 100 days |
| Gender | male |
| Strain | C3H/An |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images |  |
| Derivation | This line is a derivative of L-M(TK-) (see ATCC CCL-1.3) that is stably transfected with the gene for the human adrenergic alpha2A receptor. |
| Clinical Data | male |
| Receptor Expression | human adrenergic alpha2A, expressed |
| Comments | This line is a derivative of L-M(TK-) (see ATCC CCL-1.3) that is stably transfected with the gene for the human adrenergic alpha2A receptor. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing | Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended Medium Renewal: Two to three times weekly |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Name of Depositor | Synaptic Pharmaceutical Corporation |
| Deposited As | Mus musculus |
| U.S. Patent Number | |
| References | Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995 Lagu B, et al. Morpholinone and morpholine derivatives and uses thereof. US Patent 6,531,471 dated Mar 11 2003 Gluchowski C, et al. Use of .alpha.1C specific compounds to treat benign prostatic hyperplasia. US Patent 6,602,888 dated Aug 5 2003 Cui D, et al. Dihydropyrimidines and uses thereof . U.S. Patent 6,680,323 dated Jan 20 2004 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
